AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Why Did Zentalis Pharmaceuticals Inc. (ZNTL) Plunge 11.33%?
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Jun 5, 2025 7:13 am ET1min read
On June 5, 2025,
Inc. (ZNTL) experienced a significant drop of 11.33% in pre-market trading, reflecting a notable decline in investor sentiment.Analysts have recently weighed in on Zentalis Pharmaceuticals, with Wedbush reaffirming a "neutral" rating and setting a $4.00 price target. Meanwhile, HC Wainwright reiterated a "buy" rating with a $10.00 price objective. The average rating among analysts is "Hold," with an average target price of $8.24.
Insider activity has also been noted, with Director Scott Dunseth
acquiring 21,000 shares at an average price of $1.40 per share, increasing his ownership by 8.07%. This purchase was disclosed in a filing with the Securities and Exchange Commission.Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for various cancers. Its pipeline includes ZN-c3, an inhibitor of WEE1, which is being tested in multiple clinical trials for different cancer indications.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
ECARX Holdings plunges 8.33% in pre-market trading on investor caution ahead of earnings report and sector volatility
Dec.23 2025
WhiteFiber Surged 9.38% in Pre-Market Trading on Strategic Sector Optimism
Dec.23 2025
Dave & Buster's Entertainment shares plunge 5.70% pre-market on mixed analyst signals and Q4 revenue contraction
Dec.23 2025
BlackSky Technology (BKSY) shares rise 13.61% pre-market as Jefferies initiates coverage with Buy rating and $23 price target
Dec.23 2025
SEALSQ Surges 5.24% in Pre-Market Trading on Investor Confidence and Sector Rotation
Dec.23 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet